We are live on ! Find out more
CDAK

Codiak BioSciences, Inc. Common Stock
CDAK

Delisted

CDAK was delisted on the 4th of April, 2023.

Back to rankings

1 hedge funds and large institutions have $0 invested in Codiak BioSciences, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% less funds holding

Funds holding: 27 → 1 (-26)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $1.44M → $0 (-$1.44M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 26

Holders
1
Holders Change
-26
Holders Change %
-96.3%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
26
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
FP
Flagship Pioneering
Massachusetts
-$618K
2
LCM
Laurion Capital Management
New York
-$351K
3
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Texas
-$148K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$101K
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$78.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
FP
1
Flagship Pioneering
Massachusetts
– -$618K -3,540,636 Closed
LCM
2
Laurion Capital Management
New York
– -$351K -2,013,300 Closed
UOTTAIMCU
3
University of Texas/Texas AM Investment Management Co (UTIMCO)
Texas
– -$148K -847,108 Closed
Vanguard Group
4
Vanguard Group
Pennsylvania
– -$101K -580,770 Closed
Fidelity Investments
5
Fidelity Investments
Massachusetts
– -$78.3K -448,539 Closed
Ensign Peak Advisors
6
Ensign Peak Advisors
Utah
– -$44.1K -252,782 Closed
Millennium Management
7
Millennium Management
New York
– -$28K -161,957 Closed
FA
8
Forefront Analytics
Pennsylvania
– -$19.2K -110,210 Closed
PM
9
Parametrica Management
Hong Kong
– -$11K -65,098 Closed
Bank of America
10
Bank of America
North Carolina
– -$9.23K -53,055 Closed
HF
11
HRT Financial
New York
– -$5K -30,566 Closed
Geode Capital Management
12
Geode Capital Management
Massachusetts
– -$3.81K -21,826 Closed
HighTower Advisors
13
HighTower Advisors
Illinois
– -$4K -20,328 Closed
PFO
14
Pathstone Family Office
New Jersey
– -$2.97K -17,000 Closed
Morgan Stanley
15
Morgan Stanley
New York
– -$2.67K -15,334 Closed
Citadel Advisors
16
Citadel Advisors
Florida
– -$2.22K -12,740 Closed
VF
17
Virtu Financial
New York
– -$2K -10,491 Closed
BRWA
18
B. Riley Wealth Advisors
Florida
– -$1.75K -10,000 Closed
TRCT
19
Tower Research Capital (TRC)
New York
– -$1K -7,165 Closed
Osaic Holdings
20
Osaic Holdings
Arizona
– -$116 -667 Closed
Wells Fargo
21
Wells Fargo
California
– -$58 -332 Closed
US Bancorp
22
US Bancorp
Minnesota
– -$52 -300 Closed
IRC
23
Investors Research Corp
Georgia
– -$17 -100 Closed
UBS Group
24
UBS Group
Switzerland
– -$16 -91 Closed
SIC
25
Salem Investment Counselors
North Carolina
– -$9 -50 Closed

CDAK Hedge Fund Activity: Q2 2023 in Review

1 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Codiak BioSciences, Inc. Common Stock (CDAK) for Q2 2023, worth a combined $0 — down 100% from $1.44M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of CDAK and 0 opened new positions — a net loss of 26 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Flagship Pioneering, exiting entirely with an estimated $618K sold.

  • 1 institutional investor held Codiak BioSciences, Inc. Common Stock (CDAK) as of Q2 2023, down from 27 in Q1 2023.
  • Funds reported $0 of Codiak BioSciences, Inc. Common Stock stock for Q2 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Codiak BioSciences, Inc. Common Stock positions in Q2 2023 and 26 closed out, a net change of -26 holders.
  • The largest Codiak BioSciences, Inc. Common Stock seller in Q2 2023 was Flagship Pioneering, an estimated $618K sold.

Based on aggregated 13F filings for Q2 2023.